refining best practices in cancer immunotherapy biomarker testing and pathologic response assessment
Published 1 year ago • 537 plays • Length 1:11:32Download video MP4
Download video MP3
Similar videos
-
1:26:59
progress in immunotherapy biomarker testing and pathologic response assessment in solid tumors
-
56:08
gaining confidence in predicting and assessing response to cancer immunotherapies
-
1:03:55
the nuances of immunotherapy biomarker testing in solid tumors
-
1:14:51
the present and the future of cancer immunotherapy biomarkers
-
1:31:16
pathologic response after neoadjuvant immunotherapy: facilitating progress in early-stage cancers
-
58:57
navigating the complexities of biomarker testing in the expanding field of precision immuno-oncology
-
1:29:21
the central role of biomarker testing in piecing together the immuno-oncology puzzle
-
1:39:03
everything you need to know about biomarker testing and treatment of genomically altered nsclc
-
1:27:49
biomarker testing for new therapeutic options targeting her2, her3, and trop2 in solid tumors
-
49:36
pathway to decoding the impact of cancer immunotherapy
-
1:33:59
revisiting pd-l1 as an immunotherapy biomarker across the cancer spectrum
-
10:28
candid conversations in lung cancer: discussing biomarker testing and targeted therapies
-
28:45
refining the role of immune checkpoint inhibitors in endometrial cancer
-
59:37
marking new milestones with immunotherapy in locally advanced and early lung cancer
-
1:01:46
biomarkers, immunotherapies, combinations, and other emerging approaches for lung cancer
-
1:57:09
new concepts in immunotherapy for solid tumors
-
1:25:15
decoding biomarker testing and targeted therapy in nsclc
-
37:31
update on immuno-oncology biomarkers
-
26:32
standard and alternative dosing regimens of immunotherapies and combinations in modern oncology